Key Highlights

  • AngioDynamics (NASDAQ:ANGO) will report fiscal 2027 first quarter results before the market opens on Thursday, October 8, 2026, with a conference call at 8:00 a.m. ET, and published market data lists a consensus loss of USD 0.11.
  • Consensus Revenue near USD 80.51 million, unverified, sits below the fiscal 2027 net sales guidance of USD 336 million to USD 341 million, which averages about USD 84 million to USD 85 million per quarter.
  • Fiscal fourth quarter revenue rose 8.0% to USD 86.6 million as Med Tech grew 16.7% to USD 41.8 million, the seventh straight quarter of double-digit growth for the segment.
  • Management guided adjusted EPS to a loss of USD 0.29 to USD 0.24, adjusted EBITDA to USD 13.0 million to USD 16.0 million and gross Margin to 54% to 55% for AngioDynamics (NASDAQ:ANGO).

What Is Scheduled

AngioDynamics (NASDAQ:ANGO) announced it would report first quarter fiscal 2027 results before the open on October 8, 2026, followed by a call at 8:00 a.m. ET. This article was written before the release, so no results are known. Published market data listed a consensus loss of USD 0.11 per share on revenue of about USD 80.51 million, both single-source figures that were not verified. The guided annual range of USD 336 million to USD 341 million implies about USD 84 million to USD 85 million a quarter on average, so a first quarter near USD 80.51 million would be below the average, which is simple arithmetic and may reflect seasonality.

Where the Business Stands

For fiscal 2026, net sales were USD 320.2 million, up 9.4%, and adjusted EBITDA was USD 13.2 million versus USD 7.6 million. The company ended with USD 53.9 million of cash and no outstanding debt. In the fourth quarter, the adjusted loss of USD 0.07 compared with an expected loss of USD 0.09, and revenue of USD 86.6 million compared with USD 80.2 million expected, according to published market data. Med Tech is the growth engine, centered on platforms in cardiology and interventional oncology such as NanoKnife. Guidance expects Med Device sales to be broadly flat, so growth depends on Med Tech, and the second quarter ended November 30 will test that.

Risks and What to Watch

Risks for AngioDynamics (NASDAQ:ANGO) include a still-negative adjusted EPS outlook, dependence on a few product lines, Tariff and Supply costs, device pricing pressure, hospital Capital budgets and the chance that Med Tech growth slows from its double-digit pace. Management's Med Tech growth remarks differed across published summaries, from 12% to 15% in one and more than 18% in another quote, so investors should check the company release. Watch gross margin against the 54% to 55% target, hospital demand, any change in guidance cash use and commentary on hospital Demand in the quarter. Results on October 8, 2026 will replace this preview and any estimates here. This is not Investment advice.

Where Things Stand

AngioDynamics (NASDAQ:ANGO) investors should watch Med Tech growth, gross margin and any change to the fiscal 2027 range, because those drive the path to the guided EBITDA of USD 13.0 million to USD 16.0 million. The company has cash and no debt, but still expects an adjusted loss per share this year. The balance of evidence is constructive on growth and cautious on profit. The release before the open on October 8, 2026 will update the picture.